Showing results (11-20 of 20) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
The International Journal of Eating Disorders|May 9, 2017
Time course of the effects of lisdexamfetamine dimesylate in two phase 3, randomized, double-blind, placebo-controlled trials in adults with binge-eating disorderSusan L McElroy, James I Hudson, Maria Gasior, et al.Journal of the American Academy of Child and Adolescent Psychiatry|December 16, 2022
An Optimized Version of the Positive and Negative Symptoms Scale (PANSS) for Pediatric TrialsRobert L Findling, Eric A Youngstrom, Jon M McClellan, et al.Journal of Psychiatric Research|April 9, 2013
A comparative analysis between site-based and centralized ratings and patient self-ratings in a clinical trial of Major Depressive DisorderSteven D Targum, Pamela C Wedel, Jill Robinson, et al.Journal of Attention Disorders|January 15, 2008
Emotional expression in children treated with ADHD medication: development of a new measureAmy R Perwien, Christopher J Kratochvil, Douglas Faries, et al.Innovations in Clinical Neuroscience|January 31, 2022
Clinician- and Patient-reported Endpoints in CNS Orphan Drug Clinical Trials: ISCTM Position Paper on Best Practices for Endpoint Selection, Validation, Training, and StandardizationJoan Busner, Gahan Pandina, SilviaZaragoza Domingo, et al.Journal of Child and Adolescent Psychopharmacology|March 24, 2006
Fluoxetine 40-60 mg versus fluoxetine 20 mg in the treatment of children and adolescents with a less-than-complete response to nine-week treatment with fluoxetine 10-20 mg: a pilot studyJohn H Heiligenstein, Sharon L Hoog, Karen Dineen Wagner, et al.The American Journal of Psychiatry|November 2, 2002
Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled studyDavid Michelson, Albert J Allen, Joan Busner, et al.Journal of Child and Adolescent Psychopharmacology|September 8, 2007
Efficacy and safety of atomoxetine in adolescents with attention-deficit/hyperactivity disorder and major depression, Mark E Bangs, Graham J Emslie, et al.Journal of the American Academy of Child and Adolescent Psychiatry|August 23, 2007
High-dose atomoxetine treatment of ADHD in youths with limited response to standard dosesChristopher J Kratochvil, David Michelson, Jeffrey H Newcorn, et al.Innovations in Clinical Neuroscience|March 18, 2024
Ensuring Stakeholder Feedback in the Design and Conduct of Clinical Trials for Rare Diseases: ISCTM Position Paper of the Orphan Disease Working GroupGahan J Pandina, Joan Busner, Lucas Kempf, et al.Pageof 2